What does this research mean for the field?

Ibrutinib use is associated with reports of ventricular arrhythmia within the FDA Adverse Event Reporting System. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

May 24, 2018Leukemia & lymphoma/Leukemia and lymphoma

Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System

View Full Paper

Ask AI

Bookmark

Abstract

"Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System." Leukemia & Lymphoma, 59(12), pp. 3016–3017

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cheng et al. (2018) studied this question.

synapsesocial.com/papers/6a1fb3fee47f012c48075fcb https://doi.org/10.1080/10428194.2018.1457149

View Full Paper

Ask AI

Bookmark

Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System

Abstract

Discussion

Cite This Study

Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System

Abstract

Discussion

Cite This Study

Keep reading

Keep reading